THROMBOTIC MICROANGIOPATHY AS THE FIRST MANIFESTATION OF DISSEMINATED MALIGNANT DISEASE
Abstract
Introduction: Thrombotic microangiopathies are a group of diseases characterized by disseminated intravascular thrombosis, thrombocytopenia and ischemic organ damage. This group includes thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. One of the causes of thrombotic microangiopathy, although rare, can also be malignant diseases, primarily cancers of the stomach, prostate, breast and lungs.
Case report: We present a patient with thrombotic microangiopathy and disseminated malignant disease of unclear etiology.
Conclusion: This clinical entity is called carcinoma-associated thrombotic microangiopathy and was first described in 1970. However, only a few dozen cases have been described to date. Considering the high mortality, it should be considered in patients with malignant disease, microangiopathic hemolytic anemia, and thrombocytopenia.
References
1. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017 Jan 30;189(4):E153-E159. doi: 10.1503/cmaj.160142.
2. Said A, Haddad RY, Stein R, Lerma EV. Thrombotic thrombocytopenic purpura. Dis Mon. 2014 Oct;60(10):500-4. doi: 10.1016/j.disamonth.2014.08.005.
3. Corrigan JJ Jr, Boineau FG. Hemolytic-uremic syndrome. Pediatr Rev. 2001 Nov;22(11):365-9.
4. Brain MC, Azzopardi JG, Baker LR, Pineo GF, Roberts PD, Dacie JV. Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol. 1970 Feb;18(2):183-93. doi: 10.1111/j.1365-2141.1970.tb01433.x.
5. Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016 Jun 28;10:649. doi: 10.3332/ecancer.2016.649.
6. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012 Jul;91(4):195-205. doi: 10.1097/MD.0b013e3182603598.
7. Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2013;2013:292-9. doi: 10.1182/asheducation-2013.1.292.
8. Otrock ZK, Taher AT, Makarem JA, Kattar MM, Nsouli G, Shamseddine AI. Thrombotic thrombocytopenic purpura and bone marrow necrosis associated with disseminated gastric cancer. Dig Dis Sci. 2007 Jun;52(6):1589-91. doi: 10.1007/s10620-006-9407-7.
9. Rauh MJ, Al Habeeb A, Chang H. Microangiopathic hemolytic anemia and leukoerythroblastic blood film heralding bone marrow metastatic gastroesophageal adenocarcinoma. Pathol Res Pract. 2011 Feb 15;207(2):121-3. doi: 10.1016/j.prp.2010.07.003.
10. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S, Casimir N, Billemont B, Deray G. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006 Nov;21(11):3038-45. doi: 10.1093/ndt/gfl507.
11. De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 2008 Jun;87(6):495-6. doi: 10.1007/s00277-007-0429-9.
12. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001;24(7):491-501. doi: 10.2165/00002018-200124070-00002.
13. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985 Jan 1;55(1):47-50. doi: 10.1002/1097-0142(19850101)55:1<47::aid-cncr2820550108>3.0.co;2-#.
